Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2021 - Issue
Submit an article Journal homepage
131
Views
3
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Effects of Empirical Glucocorticoid Use on Severe Acute Exacerbation of COPD During Hospitalization

Ling Wu1 Department of Respiratory Medicine, The First People’s Hospital of Shuangliu District, Chengdu, People’s Republic of China
,
Nan Lan2 Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China
&
Xiaoyu Yang3 Department of Respiratory Medicine, Peking University First Hospital, Beijing, People’s Republic of ChinaCorrespondence[email protected]
Pages 2419-2431 | Published online: 24 Aug 2021

References

  • Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in china (the china pulmonary Health. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
  • Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188–207. doi:10.1183/09031936.06.00024505
  • WHO. World Health Report. Geneva: World Health Organization; 2000. Available from: http://www.who.int/whr/2000/en/statistics.htm:2000. Accessed August 18, 2021.
  • Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442
  • Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698–702. doi:10.1183/09031936.04.00121404
  • Calverley PM, Stockley RA, Seenmungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE Study. Chest. 2011;139:505–512. doi:10.1378/chest.09-2992
  • Walters JA, Wang W, Morley C, Soltani A, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;5(10):CD006897.
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2018 REPORT). Available from: http://www.goldcopd.org. Accessed August 18, 2021.
  • Sayner A, Aytemur ZA, Cirit M, Nsal P. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001;119(3):726–730. doi:10.1378/chest.119.3.726
  • Huiping LI, He G, Chu H, et al. A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD. Respirology. 2003;8(2):199–204. doi:10.1046/j.1440-1843.2003.00468.x
  • Willaert W, Daenen M, Bomans P, et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J. 2002;19(5):928. doi:10.1183/09031936.02.00268702
  • Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154(2):407. doi:10.1164/ajrccm.154.2.8756814
  • Niewoehner DE, Marcia L, Erbland MD, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1941–1947. doi:10.1056/NEJM199906243402502
  • Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698–703. doi:10.1164/ajrccm.165.5.2109093
  • Ynze P, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations. Chest. 2007;132:1741–1747.
  • Aaron SD, Katherine L, Vandemheen N, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618–2625. doi:10.1056/NEJMoa023161
  • Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–2231. doi:10.1001/jama.2013.5023
  • Erbland ML, Deupree RH, Niewoehner DE. Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): rationale and design of an equivalence trial. Veterans Administration Cooperative Trials SCCOPE Study Group. Control Clin Trials. 1998;19(4):404–417. doi:10.1016/s0197-2456(98)00011-7
  • Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
  • Walters JA, Tan DJ, White CJ. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9. doi:10.1002/14651858.CD001288.pub4
  • Janson C. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. J Thorac Dis. 2020;12(4):1561–1569. doi:10.21037/jtd.2020.02.51
  • Bafadhel M, Davies L, Calverley PM. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–791. doi:10.1183/09031936.00062614
  • Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6:421–430. doi:10.1016/S2213-2600(18)30103-6

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.